Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07501884 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

REDUCER Trial (TXA in Urethroplasty)

Study acronym: REDUCER
StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Dec 31, 2026 → Dec 31, 2027
See other at-risk trials from Amjad Alwaal, MD, MSc, FRCSC, FACS

Record History

  1. Primary completion pushed from Dec 31, 2026 to Dec 31, 2027
    • Start date: May 1, 2026 to Sep 1, 2026
    • Study completion pushed from Mar 30, 2027 to Mar 30, 2028
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will test whether tranexamic acid (TXA), a medication used to reduce bleeding, can decrease blood loss in patients having urethroplasty. Participants will be randomly assigned to receive either a single intravenous dose of TXA at the start of anesthesia or standard care without TXA. Researchers will compare hemoglobin change after surgery as well as estimated blood loss and complications.
Trial Details
NCT Number NCT07501884
Lead Sponsor Amjad Alwaal, MD, MSc, FRCSC, FACS
Conditions
(from sponsor)		 Urethral Stricture, Urethral Diseases
Related terms Hemorrhage, Urethral Diseases, Urethral Stricture
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov